SusanRRheingoldMD

Pediatric Hematology & Oncology • Philadelphia, PA

Associate Professor, Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Rheingold is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rheingold's full profile

Already have an account?

Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104
Phone+1 215-590-3535

Fax+1 215-590-3992

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1996 - 1999
Johns Hopkins UniversityResidency, Pediatrics, 1992 - 1995
Perelman School of Medicine at the University of PennsylvaniaClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2025
MD State Medical License 2021 - 2025
NC State Medical License 2021 - 2025
NJ State Medical License 2018 - 2025
PA State Medical License 1995 - 2024
NY State Medical License 2021 - 2023
AL State Medical License 1996 - 1996
IA State Medical License 1996 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
Philadelphia Magazine Castle Connolly, 2005, 2007-2008, 2010, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors Start of enrollment: 2002 Nov 01
Completed
Phase 1
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma Start of enrollment: 2003 Jan 01
Terminated
Phase 1
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Start of enrollment: 2015 Jul 03
Completed
Phase 1
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 1, Phase 2
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
Susan R Rheingold, Deepa Bhojwani, Lingyun Ji, Xinxin Xu, Meenakshi Devidas
Leukemia. 2024-11-01
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
Eric S Schafer, Teresa Rushing, Kristine R Crews, Colleen Annesley, Susan I Colace
Journal of the National Cancer Institute. 2024-11-01
2 citations
Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents.
Caroline Diorio, Laura Hernandez-Miyares, Diego A Espinoza, Brenda L Banwell, Amit Bar-Or
Blood. 2024-09-26

Journal Articles

Inotuzumab Ozogamicin in Pediatric Patients with relapsed/refractory Acute Lymphoblastic Leukemia
Deepa Bhojwani, Constance Yuan, Jennifer L McNeer, Mignon L Loh, Vilmarie Rodriguez, Susan R Rheingold, Elizabeth A Raetz, Nature
Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma
Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Susan R. Rheingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
Susan R. Rheingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Childrenâ€™s Oncology Group (COG) study.
2019 ASCO Annual Meeting - 6/1/2019
Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clini...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Tribeca Film Festival to Debut Documentary Tracing the Path to Penn Medicine and Children’s Hospital of Philadelphia’s Transformative, Personalized Cancer TherapyJune 9th, 2022
Allterum Therapeutics Completes Series Seed Offering, Builds Team with Addition of Philip Breitfeld as Chief Medical OfficerDecember 17th, 2020
Alternative Treatment Options Emerging for Relapsed Pediatric Patients with ALLNovember 27th, 2017
Join now to see all